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The brain parenchyma affords immune privilege to tissue grafts, but it is not known whether the same is true
for intracerebral viral infections. Using stereotactically guided microinjection, we have confined infection with
influenza virus A/NT/60/68 to either the brain parenchyma or the cerebrospinal fluid (CSF). A/NT/60/68
infection in the CSF elicited a comparable immune response to intranasal infection, with the production of
antiviral serum antibody, priming of antiviral cytotoxic T-cell precursors, and an antiviral proliferative
response in the draining lymph nodes. The response to virus in the CSF was detectable sooner after inoculation
than the response to intranasal virus and also involved a prolonged production of virus-specific immunoglob-
ulin A in the CSF. In contrast, there was no detectable immune response to virus infection in the brain
parenchyma by any of the parameters measured for at least 10 days after inoculation. Over the next 80 days,
46% of the mice given parenchymal virus developed low-level immune responses that did not involve CSF
antibody production, while the remaining 54% had no detectable response at any time. Thus, a virus infection
confined to the parenchymal substance of the brain primed the immune system inefficiently or not at all.
An immunological difference between the brain and other
anatomical sites was first demonstrated by intracerebral
transplantation (3). Allogeneic skin or neural grafts that are
rejected in conventional extracerebral sites survive in the
brain, although the rejection of an intracerebral graft can be
triggered by rejection of an equivalent extracerebral graft.
Thus, there is a lack of immune priming by intracerebral
grafts rather than a resistance to primed immune effectors.
There are regional differences in the degree of intracerebral
immune privilege; high degrees of major histocompatibility
complex mismatch between donor and recipient lead to a
chronic, low-grade rejection of grafts in the cerebral ventricles
but not of those in the brain parenchyma (22).
Intracerebral immune privilege is not due to a lack of lym-
phatic drainage from the brain (6). Despite the absence of
specialized lymphatic vessels, there is an efficient functional
drainage from the cerebrospinal fluid (CSF) to the deep cer-
vical lymph nodes via the nasal submucosa (2). Extracellu-
lar fluid from the brain parenchyma also reaches the nasal
submucosal lymphatics, either through the CSF or along peri-
vascular sheaths (5). Consistent with this lymphatic drainage,
intracerebral inoculation gives a greater serum antibody re-
sponse than extracerebral inoculation for a variety of inert
antigens, including a bacterial toxin (17), xenogenic erythro-
cytes (17, 18, 28), and xenogenic albumin (9, 11, 18). Xeno-
genic albumin in the brain parenchyma elicits a delayed and
diminished immune response compared to the same antigen in
the CSF but still a greater response than in extracerebral sites
(9).
However, it is difficult to extrapolate from proteins, eryth-
rocytes, or tissue grafts to infectious pathogens; differences in
the size, availability for degradation, and capacity for cell bind-
ing of antigens are all important considerations in their immu-
nogenicity. Of particular relevance to immune evasion by in-
tracerebral viruses is the lack of resident dendritic cells in the
brain parenchyma (12), since they play a key role in initiating
immune responses to cell-associated antigens in other organs
(23). Many common viruses can infect the central nervous
system and cause disease, but the importance of the site of
intracerebral infection to any immune response elicited re-
mains unknown.
Influenza virus, apart from being a common respiratory
pathogen, has been associated epidemiologically with neuro-
psychiatic disease in humans (19, 29), and the avian influenza
virus strains remain an ever-present potential source of new
neurovirulent epidemics (14, 27). Nonneurovirulent influenza
viruses such as A/NT/60/68 infect cells in the mouse brain and
produce viral proteins but undergo only a single abortive rep-
lication cycle (21) and thus remain confined to the site of
inoculation (7). They thus provide a suitable tool with which to
explore regional differences in the immunogenicity of intrace-
rebral virus infections.
Large-volume intracerebral inoculations are not contained
within a precise anatomical site and leak out of the brain
parenchyma into the CSF and bloodstream (4, 16). Such inoc-
ulations may force antigens into extracerebral sites by pres-
sure-dependent routes that do not contribute to normal lym-
phatic drainage. We have used stereotactic guidance and an
injection volume of 0.5 ml to confine infection with influenza
virus A/NT/60/68 to either the lateral cerebral ventricle (CSF)
or the anterior caudoputamen (brain parenchyma). Thus, we
have been able to determine how the intracerebral location of
a virus infection may influence its capacity to avoid immune
priming.
MATERIALS AND METHODS
Mice. C57BL/10 mice were bred at Harlan U.K. Ltd. (Bicester, United King-
dom) and kept under standard Home Office-approved conditions at the Biomed-
ical Services Unit, John Radcliffe Hospital, Oxford, United Kingdom. Intrace-
rebral injections were performed on 6- to 10-week-old mice, matched for age and
sex within each experiment. These was no difference in experimental outcome
between males and females or across the age range used.
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Viruses. Influenza virus A/NT/60/68 was obtained from A. R. Douglas (Na-
tional Institute for Medical Research, London, United Kingdom) and was grown
in 10- to 12-day-old embryonated hen eggs. The virus titer in infectious allantoic
fluid was measured by agglutination of chicken erythrocytes and by plaque assay
on MDCK cells (1). The same stock allantoic fluid was used for all experiments,
with aliquots kept at 2808C and thawed only once before being discarded. The
standard 0.5-ml inoculum of neat infectious allantoic fluid contained 5 hemag-
glutination units (HAU), 5 3 104 PFU, and 5 3 106 electron microscopic viral
particles.
Virus administration. Intracerebral injections were performed with the mice
immobilized in a stereotactic frame with the tooth bar at a level 3 mm below the
interaural line. The injection coordinates relative to bregma, confirmed by his-
tological inspection, were posterior 0.5 mm, lateral 0.8 mm, and depth 1.7 mm for
ventricular injections and anterior 1.0 mm, lateral 2.25 mm, and depth 2.5 mm
for parenchymal injections. Mice were anesthetized for the procedure with Hyp-
norm (fentanyl/fluasinone; Janssen Pharmaceuticals, Wantage, United King-
dom) and Hypnovel (midazolam; Roche, Welwyn Garden City, United King-
dom). A hole was made in the skull by using a dentist’s drill, and the virus
suspension was injected slowly by using a 26S-gauge positive-displacement Ham-
ilton syringe. The skin was sutured after a slow withdrawal of the needle, and all
mice made an uneventful recovery. Intracerebral A/NT/60/68 infection in either
site was not associated with significant clinical illness. Intranasal influenza virus
was administered under brief ether anesthesia in a volume of 30 ml.
Antibody assays. Serum and CSF anti-A/NT/60/68 antibody titers were deter-
mined by enzyme-linked immunosorbent assay (ELISA). Influenza virus was
concentrated from infectious allantoic fluid by sucrose density gradient centrif-
ugation (1) and coated overnight (400 ng/well) at 48C onto 96-well Nunc Polysorb
immunoplates (Life Technologies, Paisley, United Kingdom) in sodium bicar-
bonate (50 mM, pH 9.7)-sarcosyl (0.025%) buffer. Coated plates were washed
four times with 0.05% Tween in double-distilled H2O, and nonspecific protein
binding was blocked by incubation for 20 min with 2% bovine serum albumin in
phosphate-buffered saline–Tween (0.05%)–EDTA (1 mM). After two further
washes, duplicate fivefold serum dilutions (100 ml/well) were incubated for 1 h at
room temperature followed by five washes. All serum dilutions started at 1/30
and all CSF dilutions started at 1/200 unless otherwise stated. The secondary
antibody conjugate was then incubated for 1 h at room temperature followed by
a further five washes. The secondary antibodies used were as follows: total
immunoglobulin G (IgG), horseradish peroxidase (HRP)-coupled goat anti-
mouse Fcg (Sigma Chemical Co., Poole, United Kingdom); IgM, HRP-coupled
goat anti-mouse Fcm (Sigma); and IgA, HRP-coupled goat anti-mouse Fca
(Sigma). o-Phenylenediamine dihydrochloride (1 mg/ml; Sigma) in citrate-phos-
phate buffer (0.1 M, pH 5.5) was used as the HRP substrate, the reaction was
terminated with 3 M HCl, and the optical density (OD) was read at 492 nm.
Standard immune and naive sera were included on each plate to allow compar-
ison on a plot of OD versus log10 (concentration). Titers were calculated relative
to the immune standard for an equivalent OD reading, with this standard as-
signed an arbitary number of titer units for each immunoglobulin class, chosen
such that the background OD with 1/30 naive mouse serum was equivalent to a
titer of 1 U. Log10 titers were compared statistically by paired t test.
Neutralizing antiviral antibodies were measured by hemagglutination inhibi-
tion (HAI) assay (1). Twofold triplicate serum dilutions were made from an
initial 1/5 concentration and were incubated for 30 min at room temperature with
5 HAU of A/NT/60/68 virus. Chicken erythrocytes (Serotec, Kidlington, United
Kingdom) were then added (0.5%, final concentration), and the presence or
absence of agglutination was scored after a further 30 min. The HAI titer was
taken as the reciprocal of the last dilution inhibiting erythrocyte agglutination by
the virus in at least two of three wells.
Cytotoxic T-lymphocyte (CTL) restimulation. Spleens were aseptically re-
moved, pooled from pairs of mice, and disrupted into single-cell suspensions.
Naive syngeneic feeder spleen cells were incubated for 1 h at 378C with 200 HAU
of influenza virus A/NT/60/68 per 106 cells in RPMI (Life Technologies), irra-
diated (20 Gy), and washed twice in RPMI supplemented with 50 mM 2-mer-
captoethanol, 60 mg of penicillin per ml, 100 mg of streptomycin per ml, 2 mM
glutamine, and 10% fetal calf serum (FCS; Globepharm, Esher, United King-
dom) (complete medium). Responder spleen cells (106/ml) and feeder spleen
cells (3 3 105/ml) were cultured for 5 days at 378C with 5% CO2 in 15 ml of
complete medium before testing of cytotoxicity (24).
CTL assay. EL-4 target cells (H-2b) were labelled with 51Cr (100 mCi; Amer-
sham International, Amersham, United Kingdom) for 1 h at 378C, washed once,
and then incubated with medium alone, pulsed with the H-2Db-restricted immu-
nodominant influenza virus nucleoprotein peptide (1 mM ASNENMDAM,
kindly provided by N. Groome, Oxford Brookes University, Oxford, United
Kingdom) (25), or infected with A/NT/60/68 virus (500 HAU/106 cells). After 1 h
at 378C, the targets were washed twice in complete medium and incubated (104
EL-4 cells/well) with effector cells for 4 h before harvesting of supernatants for
scintillation counting. Targets with effectors were measured in duplicate, and
target controls with Triton or medium alone were measured in quadruplicate.
The percent specific lysis was calculated as 100 3 (release by CTL 2 release by
targets alone)/(release by Triton 2 release by targets alone). The 51Cr released
with medium alone was 5 to 15% of that released by Triton.
Proliferation assay. Lymph nodes were aseptically removed, pooled from pairs
of mice, and disrupted into single-cell suspensions. Lymph node cells (2 3 105)
were mixed with irradiated syngeneic feeder spleen cells (5 3 105) in quadru-
plicate 150-ml cultures. Feeder cells were either unpulsed, infected with influenza
virus A/NT/60/68 as for CTL restimulation, or mixed with phytohemagglutinin
(PHA) at a final concentration of 10 mg/ml (Sigma). The response to PHA gave
an indication of the total number of potentially responsive cells; 10 mg/ml elicits
an optimal mitogenic response in this assay system. Culture conditions were as
for CTL restimulation (above) except that 1% naive homologous mouse serum
was used in place of 10% FCS. After 3 days, 1 mCi of [3H]thymidine (Amersham
International) was added to each well, and the cells were harvested for scintil-
lation counting of incorporated label 18 h later.
Immunohistochemistry. Brains were dissected free of the cranium and outer
meninges and quickly frozen in liquid nitrogen. Cryostat sections (7 to 10 mm)
were air dried and fixed in acetone for 10 min before staining. All subsequent
steps were carried out at room temperature. The sections were preincubated in
10% goat serum and incubated for 1 h with an anti-influenza virus ribonucleo-
protein rabbit serum (20), kindly provided by C. Scholtissek (Department of
Virology, Justus Liebig University, Giessen, Germany). An HRP-conjugated
goat anti-rabbit serum (Vector Laboratories, Peterborough, United Kingdom)
was used as the secondary antibody. The sections were washed three times in
phosphate-buffered saline with 1% FCS after each incubation. Endogenous
FIG. 1. Early serum anti-A/NT/60/68 antibody responses after intranasal,
parenchymal, or ventricular virus inoculation. Intranasal or ventricular but not
parenchymal virus inoculations led to the production of specific serum antibody.
Means and standard errors of 12 mice per time point from four trials are shown
for IgG and IgM titers and for 6 mice per time point from two trials for HAI
titers. Log2 (titer) 5 1.6 is the lower limit of HAI assay sensitivity.
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peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol after
incubation with the primary antibody. Diaminobenzidine (Sigma) was used as the
HRP substrate, sections were counterstained with hematoxylin (Sigma), and
slides were mounted with DPX (Merck Ltd., Poole, United Kingdom).
RESULTS
Early antibody response to virus in different sites. Mice
were infected with 5 HAU of influenza virus A/NT/60/68 in
either the left lateral cerebral ventricle (CSF), the left anterior
caudoputamen (brain parenchyma), or the lung. The efficacy of
immune priming by each route was determined over the fol-
lowing 10 days by ELISA measurement of total antiviral IgG
and IgM and HAI assay of neutralizing antiviral antibody (Fig.
1). Ten days after intranasal or ventricular A/NT/60/68 infec-
tion, virus-specific IgG was detectable at a serum dilution of
1/105; 10 days after parenchymal infection, virus-specific IgG
was undetectable at a serum dilution of 1/2.
Early cellular response to virus in different sites. The pres-
ence of a virus-specific immune response in the draining lymph
nodes was determined 10 days after inoculation by prolifera-
tion assay. Virus-specific proliferation was evident with intra-
nasal or ventricular but not with parenchymal virus infections,
despite equivalent responses to PHA stimulation (Fig. 2). The
high spontaneous proliferation rates seen with mice given in-
tranasal or ventricular virus were probably due to the contin-
ued division of cells activated in vivo and to the presence in the
responder population of cells presenting viral antigens ac-
quired in vivo. This proliferation provided a further indication
of immune activation.
The same mice were tested for the presence of primed CTL
precusors 10 days after virus inoculation by restimulating
spleen cells in vitro with A/NT/60/68-infected feeder cells prior
to cytotoxicity assay (Fig. 3). These results again correlated
with the serum antibody titers; virus-specific CTL were primed
by intranasal or ventricular infections but not by parenchymal
infection. Virus-specific CTL precursors were also detected in
the deep cervical lymph nodes of mice given ventricular but not
parenchymal A/NT/60/68 (not shown). In six separate trials,
there was a consistent agreement between the different immu-
nological parameters; intranasal or ventricular virus always
induced specific antibody in the serum, a proliferative response
in the lymph nodes, and CTL precursors in the spleen, whereas
parenchymal virus failed to induce a response by any of these
criteria.
Timing of the immune response to ventricular virus infec-
tion. Although ventricular virus infection did not elicit a
greater antibody response than intranasal infection, specific
serum IgG and IgM were both detectable sooner after virus
inoculation into the CSF (Fig. 1). The antiviral antibody re-
sponse to ventricular influenza virus infection exceeded that to
intranasal infection at day 3 (P , 0.0001 for IgM) and day 5
(P , 0.001 for IgM and P , 0.001 for IgG) after virus inocu-
lation.
To determine whether the sensitization of antigen-specific
cells in the draining lymph nodes was also more rapid after
infection in the CSF, the proliferative responses to ventricular
and intranasal virus infections were followed with time after
inoculation (Fig. 4). The response to ventricular virus reached
high levels by day 3, 2 days earlier than the response to intra-FIG. 2. Proliferative response of cells from the draining lymph nodes 10 days
after intranasal, parenchymal, or ventricular virus inoculation. Deep cervical
lymph nodes were taken from mice given parenchymal and ventricular virus,
mediastinal lymph nodes were taken from mice given intranasal virus, and both
sets of lymph nodes (pooled) were taken from naive mice. Cells were pooled
from pairs of mice, and each bar shows the mean and standard error of three
pairs.
FIG. 3. Cytotoxic activity of restimulated spleen cells 10 days after intranasal,
parenchymal, or ventricular virus inoculation. Spleen cells pooled from pairs of
mice were restimulated in vitro as described in Materials and Methods before
testing of cytotoxicity against EL-4 (H-2b) target cells. Means and standard errors
of three pairs of mice are shown in each case. ASNENMDAM is the H-2Db-
restricted immunodominant influenza virus A/NT/60/68 nucleoprotein epitope.
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nasal virus, corresponding to the earlier onset of serum anti-
body production after ventricular virus inoculation. Primed
virus-specific splenic CTL precursors, however, were detect-
able at the same time after ventricular or intranasal immuni-
zations (Fig. 5).
Late immune response to intracerebral virus. Immunohis-
tochemistry showed that there was widespread infection of the
ependymal cells 1 day after ventricular virus inoculation, but
after 10 days, considerable destruction of the ependymal cells
had taken place and antiviral staining was minimal (Fig. 6).
Virus-infected cells were visible at both 1 and 10 days after
parenchymal virus inoculation (Fig. 6) but not in either site
after 1 month, when the viral nucleoprotein gene was also
undetectable by PCR amplification from total brain cDNA
(not shown). Since the nonreplicating virus was apparently lost
from the brain by 1 month after inoculation, virus-specific
serum antibody was measured by ELISA over 3 months to
detect delayed immune responses. Spleen cells from the same
mice were restimulated in vitro 3 months after inoculation to
detect late CTL priming (Fig. 7). In 7 of 13 (54%) mice given
parenchymal virus, there was no detectable antibody at any
time. In the remaining 6 (46%) of the 13 mice no antibody was
detectable after 10 days but low levels were found from 1 to 3
months, typically maximal at 1 month followed by a slow de-
cline. The presence of primed CTL precursors in the spleen 3
months after parenchymal virus inoculation correlated with the
presence of specific serum IgG; mice either had low levels of
both or were negative for both. No mice given parenchymal
virus had detectable anti-A/NT/60/68 HAI antibody at any
time (not shown).
Virus-specific antibody in the CSF. Ventricular infection
with influenza virus A/NT/60/68, as with large-volume intrace-
rebral inoculations of other viruses (8, 10), led to a local pro-
duction of virus-specific immunoglobulin in the CSF (Table 1).
Low levels of A/NT/60/68-specific IgG were present in the CSF
10 days after both ventricular and intranasal immunizations,
with similar CSF/serum specific IgG ratios, suggesting that the
IgG in the CSF was largely derived from that in the serum. But
whereas mice given intranasal virus had moderate serum an-
tiviral IgA levels and undetectable CSF levels, mice given ven-
tricular virus had low serum antiviral IgA levels and high CSF
levels, consistent with a local synthesis of virus-specific IgA in
the CSF. Serum antiviral IgA reached higher levels 90 days
after ventricular virus inoculation, accompanied by some dim-
inution in CSF levels. Antiviral IgG or IgA was not detected in
the CSF of mice given parenchymal A/NT/60/68 at any time.
DISCUSSION
Viral immunogenicity in the CSF and the brain paren-
chyma. Large-volume (5- or 30-ml) virus inoculations into the
brain parenchyma elicited antibody, proliferation, and cytotox-
icity responses equivalent to those elicited by ventricular inoc-
ulations (not shown), consistent with a leakage of virus fromFIG. 4. Time course of proliferative responses from the draining lymph
nodes after intranasal or ventricular virus inoculation. Means and standard
errors of three trials are shown, each trial including cells pooled from a pair of
mice for each time point and for each route of immunization. Dcpm 5 cpm with
the stimulus indicated 2 cpm with unpulsed feeders. The [3H]thymidine incor-
poration with unpulsed feeders in these trials did not exceed 1,000 cpm at days
1 to 3, 5,000 cpm at days 5 to 7, or 10,000 cpm at day 10. The response to PHA
provided an indicator of the total number of potentially responsive cells in the
assay regardless of antigen specificity. For day 1 ventricular and day 1 to 3
intranasal immunizations, the proliferative response with A/NT/60/68-infected
feeders was less than three times the response with uninfected feeders and was
not considered to be significant. The anti-influenza virus response after paren-
chymal virus infection did not exceed Dcpm5 500 at any time point (not shown).
FIG. 5. Cytotoxic activity of restimulated spleen cells with time after intra-
nasal or ventricular virus inoculation. Means and standard errors of three trials
are shown, each trial including cells from a pooled pair of mice for each time
point and for each route of immunization. Net % specific lysis 5% specific lysis
of indicated target 2 % specific lysis of unpulsed targets. Specific lysis of EL-4
cells alone did not exceed 15% at any time point. Net specific lysis after paren-
chymal virus infection did not exceed 4% at any time point (not shown).
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the parenchyma into the CSF. Small-volume (0.5-ml) virus
inoculations remained confined to the site of inoculation and
showed a clear difference in immunogenicity between the lat-
eral cerebral ventricle, where infection primed the immune
system to a degree comparable with intranasal immunization,
and the brain parenchyma, where infection led only to incon-
sistent, delayed, low-level responses. Apart from the relative
rapidity of the response to ventricular virus infection, there
were surprisingly few differences between the immune re-
sponses to virus in the CSF and to virus in the lung. The local
intracerebral immunoglobulin response to influenza virus in-
fection involved IgA production in the CSF (Table 1), analo-
gous to the mucosal IgA response seen with intranasal virus
infection (13).
The fate of influenza virus antigens in the CSF. The deep
cervical lymph nodes are the main site of an immune response
to antigens in the intracranial CSF (11, 15). Although antigens
injected intracerebrally have also been associated with immune
responses being initiated in the spleen (26, 28), without the use
of small-volume and hence low-pressure injections, direct leak-
age into the bloodstream by nonphysiological routes cannot be
ruled out (4, 16). Small-volume inoculations of influenza virus
A/NT/60/68 into the CSF led first to the sensitization of virus-
specific cells in the draining lymph nodes (Fig. 4) and then to
the appearance of virus-specific antibody in the serum (Fig. 1)
and CTL precursors in the spleen (Fig. 5). This was consistent
with a primary role for the cervical lymph nodes in the immune
response. As with Sindbis virus encephalitis (26), synthesis of
virus-specific antibody in the CSF was a relatively late event;
A/NT/60/68-specific antibody was not detectable in the CSF 7
days after ventricular virus inoculation (not shown), when spe-
cific antibody was abundant in the serum (Fig. 1).
FIG. 6. Intracerebral virus infection 1 and 10 days after parenchymal or
ventricular virus inoculation. Anti-influenza virus ribonucleoprotein staining is
shown, either 1 day (A and C) or 10 days (B and D) after inoculation of 5 HAU
of A/NT/60/68 virus into either the anterior caudoputamen (A and B) or the
lateral cerebral ventricle (C and D). Arrows indicate examples of infected cells.
After parenchymal virus inoculation, infected intracerebral cells were seen after
both 1 day (A) and 10 days (B). After ventricular virus inoculation, almost all the
ependymal cells had been infected after 1 day (C), but after 10 days, the virus-
infected ependymal lining had largely disappeared. The bar in panel D repre-
sents 500 mm for each panel.
FIG. 7. Late immune response after parenchymal or ventricular virus inoc-
ulation. The upper diagram shows A/NT/60/68-specific serum IgG responses
over 3 months following virus inoculation, with means and standard errors of six
to seven mice per arm pooled from two trials. The mice given parenchymal virus
are shown as two separate groups, those which developed late antibody and those
which did not. The lower diagram shows the cytotoxic activity of spleen cells from
the mice in one representative trial, restimulated in vitro with A/NT/60/68-
infected syngeneic spleen cells 3 months after intracerebral virus inoculation. Net
% specific lysis 5 % specific lysis of indicated target 2 % specific lysis of EL-4
cells alone. The specific lysis of EL-4 cells alone did not exceed 15%. Spleen cells
from each mouse were restimulated and tested separately; means and standard
errors of three mice in each arm are shown.
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However, we were unable to demonstrate directly viral an-
tigens in the deep cervical lymph nodes after inoculation into
the CSF. The viral nucleoprotein gene was undetectable by
PCR amplification from cervical lymph node cDNA 1 to 3 days
after ventricular virus inoculation, despite being readily ampli-
fied from whole brain cDNA at the same time (not shown).
Immunohistochemistry also failed to detect the viral nucleo-
protein in the deep cervical lymph nodes (not shown), despite
its presence in the brain (Fig. 6). These negative results sug-
gested that the antigen reaching the draining lymph nodes
either was only a small proportion of the initial inoculum or
was present in a different form to the infected cells in the brain.
Indirect evidence of immunogenic viral antigens reaching the
draining lymph nodes soon after ventricular inoculation was
provided by the antiviral proliferative responses (Fig. 4).
The more rapid response to ventricular than to intranasal
virus infection was probably due to viral antigens reaching the
draining lymphatics directly from CSF (2), whereas intranasal
influenza virus first had to cross the respiratory epithelium. A
direct entry into lymphatics, avoiding degradation by tissue
macrophages and proteases, could also explain the increased
intracerebral immunogenicity of a variety of inert antigens
(9, 11, 17, 18, 28). An exact quantitative comparison between
intranasal and intracerebral virus infections was not possible,
since influenza virus A/NT/60/68 replicated productively in the
mouse lung (not shown) but not in the mouse brain (21).
After ventricular or larger-volume virus inoculations, influ-
enza virus-specific proliferation was frequently seen (six of
nine pairs of mice tested) with cells from the abdominal para-
aortic lymph nodes and less often (two of nine pairs of mice
tested) with cells from the mediastinal lymph nodes (not
shown). These responses were never present without a re-
sponse in the deep cervical lymph nodes and suggested that
virus in the lateral cerebral ventricle may also be carried by
CSF flow to more caudal sites with separate lymphatic drain-
age pathways.
The fate of influenza virus antigens in the brain paren-
chyma. The simplest interpretation of the lack of response to
parenchymal virus infection was that antigens failed to reach
the draining lymph nodes. Protein antigens drain efficiently
from the brain parenchyma to the cervical lymph nodes (6)
and initiate immune responses (9). Influenza virions, however,
bind to the abundant sialic acid on cell surfaces and were
probably endocytosed before leaving the extracellular spaces
of the brain parenchyma. Without virus-infected dendritic cells
reaching the lymph nodes, the intracellular viral antigens re-
mained immunologically unseen.
The late low-grade immune responses to parenchymal influ-
enza virus may have resulted from the eventual breakdown of
infected cells (when virus was no longer detectable by immu-
nohistochemistry), with viral protein debris being released into
the extracellular spaces. Since a late immune response was
detected in fewer than half of the mice tested, such debris may
often have been degraded before leaving the brain. Neverthe-
less, persistent immune evasion by intracerebral viruses,
whether natural pathogens or used as vehicles for gene ther-
apy, probably depends upon the infected cells not undergoing
apoptosis.
Implications for intracerebral virus infection. Although vi-
ruses often replicate in extracerebral sites before reaching the
brain, congenital transmission, infection of circulating lympho-
cytes, and retrograde transport along peripheral neurons are
all ways by which viruses may reach the brain without first
initiating an immune response. These viruses could then re-
main in the brain parenchyma without priming the immune
system. In addition, viruses are able to vary their gene expres-
sion according to the cell type infected, and viral proteins
expressed specifically in the brain would be unrecognized by
the immune system. When immune privilege does contribute
to viral persistence, specific extracerebral immune priming
might be one way of eliminating infection from the central
nervous system.
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